Analyst Viewpoint
Surge in prevalence of cancer is one of the key factors boosting metastatic bone disease market size. Rise in geriatric population and growth in adoption of unhealthy lifestyle have led to an increase in the prevalence of cancer. Metastatic bone disease is a cancer that originates from one organ and spreads to bones, causing severe pain and reducing the standard of living and life expectancy of patients. Increase in government spending on cancer awareness campaigns is also augmenting metastatic bone disease industry revenue.
Doctors and experts in oncology prefer treating patients suffering from metastatic bone disease with chemotherapy, as it helps in pain management and improving survival rates. Prominent players in the global metastatic bone disease market are striving to develop novel radiopharmaceutical drugs for the treatment of breast and prostate cancers.
Metastatic bone disease (MBD) is a form of cancer that originates from one organ of the body and spreads to bones. Any type of cancer can spread from its original site to the bone; however, breast and prostate cancers are more likely to spread to bones. Other cancers with low but significant probability of metastasis include thyroid, kidney, and lung cancers.
Spine, pelvis, and ribs are the most common regions of the spread of cancer. These sites are also crucial areas of bone marrow, which is responsible for producing high amount of red blood cells. Red blood cells play a vital role in transporting oxygen to tissues in the human body.
MBD causes severe pain in the area of the spread and can lead to weakness in the bone. Everyday activities such as standing and walking can become arduous for an individual. Fracture is common in patients suffering from MBD. Patients with fractures or impending fractures are recommended bed rest for a long duration of time. This severely hampers the quality of life of patients.
Cancer is a globally prevalent disease and a leading cause of death worldwide. According to data made publicly available by the WHO, the disease accounts for nearly one in six deaths. As per the WHO, cancer-causing infections, such as hepatitis, accounted for nearly one-third of cancer cases in lower and middle income countries in 2022.
Significant increase in geriatric population and rise in adoption of unhealthy lifestyle across age groups have worsened the prevalence of cancer across the globe.
As per the American Association for Cancer Research, national cancer care costs are expected to exceed US$ 245.0 Bn in the U.S. by 2030. Thus, increase in expenditure on cancer care is likely to augment the metastatic bone disease market.
Healthcare practitioners and cancer care clinics prefer to treat MBD with chemotherapy and hormone therapy in an attempt to enhance the patient’s survival rate and offer the best pain management.
Surge in number of cancer awareness programs is contributing to an improvement in patient education, thus leading to earlier diagnosis and screenings. Early detection and diagnosis of cancer may increase the patient’s chances of survival drastically.
Recent medical research indicates that the survival rate of most cancers at one and five years is higher if the cancer is detected early (at stage one).
Consistent efforts by governments and other stakeholders regarding self-screening and awareness about the different types of cancer assist in early screening and diagnosis of the disease.
Several countries across the globe, including the U.K. and the U.S., are playing a significant role in funding cancer research and promoting cancer awareness. The Cancer Research UK conducts campaigns such as the ‘Race for Life’ and ‘Stand Up to Cancer,’ while the American Cancer Society carries out campaigns such as the ‘Great American Smokeout’ and ‘Relay for Life.’ These campaigns promote healthy lifestyles and eating habits, and have raised funds for research while improving survival rates.
According to the latest metastatic bone disease market analysis, North America accounted for the largest share in 2022. Presence of a well-developed healthcare sector and R&D in novel clinical cancer therapies are augmenting the market dynamics of the region.
As per a research paper in the Annals of Joint, metastatic bone disease affects nearly 300,000 to 600,000 adults in the U.S.
According to the latest metastatic bone disease market forecast, Asia Pacific is likely to be a lucrative region in the near future, led by the expansion in the medical tourism industry and rise in awareness regarding cancer care in the region.
As per a report by the Federation of Indian Chambers of Commerce & Industry (FICCI), India received around 650,000 medical tourists in 2022. The country ranks seventh among the top 20 wellness tourism markets across the globe.
Thus, the metastatic bone disease market share of Asia Pacific is projected to increase at a steady pace during the forecast period.
According to recent metastatic bone disease market trends, prominent players are investing substantially in the development of novel drugs and computational technologies to solve critical issues for both patients and healthcare workers.
Early detection of breast cancer that has metastasized to the bone or breast cancer spread to bones is a crucial focus of key players in the metastatic bone disease industry. Leading players are also seeking to introduce targeted therapies for metastatic bone lesions to improve patient outcome.
Amgen, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Bayer AG, Fresenius Kabi AG, Boston Scientific Corporation, and Medtronic are the prominent firms operating across the global landscape.
The metastatic bone disease market report summarizes the leading players in terms of parameters such as company overview, business strategies, product portfolio, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 17.0 Bn |
| Market Forecast Value in 2031 | US$ 36.4 Bn |
| Growth Rate (CAGR) | 8.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 17.0 Bn in 2022
It is projected to grow at a CAGR of 8.7% from 2023 to 2031
Rise in prevalence of cancer and increase in cancer awareness programs
The medication segment accounted for the largest share in 2022
North America was the leading region in 2022
Amgen, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Bayer AG, Fresenius Kabi AG, Boston Scientific Corporation, and Medtronic
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Metastatic Bone Disease Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Metastatic Bone Disease Market Analysis and Forecast, by Treatment
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Medication
6.3.1.1. Chemotherapy
6.3.1.2. Hormone Therapy
6.3.1.3. Bisphosphonates
6.3.1.4. Opiate Therapy
6.3.1.5. Immunotherapy
6.3.2. Radiation Therapy
6.3.3. Surgical Intervention
6.3.4. Tumor Ablation Therapy
6.4. Market Attractiveness, by Treatment
7. Global Metastatic Bone Disease Market Analysis and Forecast, by Origin of Metastasis
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Origin of Metastasis, 2017–2031
7.3.1. Breast
7.3.2. Lung
7.3.3. Thyroid
7.3.4. Kidney
7.3.5. Prostate
7.3.6. Others
7.4. Market Attractiveness, by Origin of Metastasis
8. Global Metastatic Bone Disease Market Analysis and Forecast, by Provider Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Provider Type, 2017–2031
8.3.1. OEM
8.3.2. Non-OEM
8.4. Market Attractiveness, by Provider Type
9. Global Metastatic Bone Disease Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Attractiveness, by End-user
10. Global Metastatic Bone Disease Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Metastatic Bone Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Medication
11.2.1.1. Chemotherapy
11.2.1.2. Hormone Therapy
11.2.1.3. Bisphosphonates
11.2.1.4. Opiate Therapy
11.2.1.5. Immunotherapy
11.2.2. Radiation Therapy
11.2.3. Surgical Intervention
11.2.4. Tumor Ablation Therapy
11.3. Market Attractiveness, by Treatment
11.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
11.4.1. Breast
11.4.2. Lung
11.4.3. Thyroid
11.4.4. Kidney
11.4.5. Prostate
11.4.6. Others
11.5. Market Attractiveness, by Origin of Metastasis
11.6. Market Value Forecast, by Provider Type, 2017–2031
11.6.1. OEM
11.6.2. Non-OEM
11.7. Market Attractiveness, by Provider Type
11.8. Market Value Forecast, by End-user
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Ambulatory Surgical Centers
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment
11.11.2. By Origin of Metastasis
11.11.3. By Provider Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Metastatic Bone Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Medication
12.2.1.1. Chemotherapy
12.2.1.2. Hormone Therapy
12.2.1.3. Bisphosphonates
12.2.1.4. Opiate Therapy
12.2.1.5. Immunotherapy
12.2.2. Radiation Therapy
12.2.3. Surgical Intervention
12.2.4. Tumor Ablation Therapy
12.3. Market Attractiveness, by Treatment
12.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
12.4.1. Breast
12.4.2. Lung
12.4.3. Thyroid
12.4.4. Kidney
12.4.5. Prostate
12.4.6. Others
12.5. Market Attractiveness, by Origin of Metastasis
12.6. Market Value Forecast, by Provider Type, 2017–2031
12.6.1. OEM
12.6.2. Non-OEM
12.7. Market Attractiveness, by Provider Type
12.8. Market Value Forecast, by End-user, 2017–2031
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Ambulatory Surgical Centers
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment
12.11.2. By Origin of Metastasis
12.11.3. By Provider Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Medication
13.2.1.1. Chemotherapy
13.2.1.2. Hormone Therapy
13.2.1.3. Bisphosphonates
13.2.1.4. Opiate Therapy
13.2.1.5. Immunotherapy
13.2.2. Radiation Therapy
13.2.3. Surgical Intervention
13.2.4. Tumor Ablation Therapy
13.3. Market Attractiveness, by Treatment
13.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
13.4.1. Breast
13.4.2. Lung
13.4.3. Thyroid
13.4.4. Kidney
13.4.5. Prostate
13.4.6. Others
13.5. Market Attractiveness, by Origin of Metastasis
13.6. Market Value Forecast, by Provider Type, 2017–2031
13.6.1. OEM
13.6.2. Non-OEM
13.7. Market Attractiveness, by Provider Type
13.8. Market Value Forecast, by End-user, 2017–2031
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Ambulatory Surgical Centers
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment
13.11.2. By Origin of Metastasis
13.11.3. By Provider Type
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Metastatic Bone Disease Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Medication
14.2.1.1. Chemotherapy
14.2.1.2. Hormone Therapy
14.2.1.3. Bisphosphonates
14.2.1.4. Opiate Therapy
14.2.1.5. Immunotherapy
14.2.2. Radiation Therapy
14.2.3. Surgical Intervention
14.2.4. Tumor Ablation Therapy
14.3. Market Attractiveness, by Treatment
14.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
14.4.1. Breast
14.4.2. Lung
14.4.3. Thyroid
14.4.4. Kidney
14.4.5. Prostate
14.4.6. Others
14.5. Market Attractiveness, by Origin of Metastasis
14.6. Market Value Forecast, by Provider Type, 2017–2031
14.6.1. OEM
14.6.2. Non-OEM
14.7. Market Attractiveness, by Provider Type
14.8. Market Value Forecast, by End-user, 2017–2031
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Ambulatory Surgical Centers
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment
14.11.2. By Origin of Metastasis
14.11.3. By Provider Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017–2031
15.2.1. Medication
15.2.1.1. Chemotherapy
15.2.1.2. Hormone Therapy
15.2.1.3. Bisphosphonates
15.2.1.4. Opiate Therapy
15.2.1.5. Immunotherapy
15.2.2. Radiation Therapy
15.2.3. Surgical Intervention
15.2.4. Tumor Ablation Therapy
15.3. Market Attractiveness, by Treatment
15.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
15.4.1. Breast
15.4.2. Lung
15.4.3. Thyroid
15.4.4. Kidney
15.4.5. Prostate
15.4.6. Others
15.5. Market Attractiveness, by Origin of Metastasis
15.6. Market Value Forecast, by Provider Type, 2017–2031
15.6.1. OEM
15.6.2. Non-OEM
15.7. Market Attractiveness, by Provider Type
15.8. Market Value Forecast, by End-user, 2017–2031
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Ambulatory Surgical Centers
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment
15.11.2. By Origin of Metastasis
15.11.3. By Provider Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Amgen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Merck & Co., Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Novartis AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Eli Lilly and Company
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Bayer AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Fresenius Kabi AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Boston Scientific Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Medtronic
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
List of Tables
Table 01: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031
Table 03: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031
Table 04: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 05: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 08: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031
Table 09: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031
Table 10: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 11: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 13: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031
Table 14: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031
Table 15: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 18: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031
Table 19: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031
Table 20: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 23: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031
Table 24: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031
Table 25: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 28: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031
Table 29: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031
Table 30: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Metastatic Bone Disease Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Treatment, 2022
Figure 03: Global Metastatic Bone Disease Market Value Share, by Treatment, 2022
Figure 04: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Origin of Metastasis, 2022
Figure 05: Global Metastatic Bone Disease Market Value Share, by Origin of Metastasis, 2022
Figure 06: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Provider Type, 2022
Figure 07: Global Metastatic Bone Disease Market Value Share, by Provider Type, 2022
Figure 08: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
Figure 09: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
Figure 10: Global Metastatic Bone Disease Market Value Share, by Region, 2022
Figure 11: Global Metastatic Bone Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 12: Global Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 13: Global Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 14: Global Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 15: Global Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 16: Global Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 17: Global Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 18: Global Metastatic Bone Disease Market Revenue (US$ Mn), by End-user, 2022
Figure 19: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
Figure 20: Global Metastatic Bone Disease Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Metastatic Bone Disease Market Attractiveness Analysis, by Region, 2023-2031
Figure 22: North America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 23: North America Metastatic Bone Disease Market Attractiveness Analysis, by Country, 2023–2031
Figure 24: North America Metastatic Bone Disease Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 26: North America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 27: North America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 28: North America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 29: North America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 30: North America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031
Figure 31: North America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031
Figure 32: North America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031
Figure 33: Europe Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 34: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 37: Europe Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 38: Europe Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 39: Europe Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 41: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031
Figure 42: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031
Figure 43: Europe Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031
Figure 44: Asia Pacific Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 45: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 48: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 49: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 50: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2017–2031
Figure 52: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031
Figure 53: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031
Figure 54: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031
Figure 55: Latin America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 56: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 57: Latin America Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Latin America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 59: Latin America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 60: Latin America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 61: Latin America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 62: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 63: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031
Figure 64: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031
Figure 65: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031
Figure 66: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 67: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 68: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 69: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 70: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 71: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 72: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 73: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 74: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031
Figure 75: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031
Figure 76: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Metastatic Bone Disease Market
*86 figures and 60 tables includes